Key Factors Fueling the Growth of the Cancer Anorexia-Cachexia Syndrome (CACS) Market in 2025: Impact Of Rising Cancer Prevalence On The Market
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the Anticipated CAGR of the Cancer Anorexia-Cachexia Syndrome (CACS) Market, and What Factors Will Drive It?
The market for the cancer anorexia-cachexia syndrome (CACS) has seen a swift expansion in the past few years. The market is forecasted to surge from $3.51 billion in 2024 to $3.89 billion in 2025, progressing at a compound annual growth rate (CAGR) of 11.0%. Factors contributing to the growth experienced in the previous period include a rise in cancer cases, heightened awareness amongst healthcare professionals, an enhanced emphasis on the quality of life for cancer patients, widening clinical trials, and increased collaborations and partnerships within the pharmaceutical industry.
The market for cancer anorexia-cachexia (CACS) is projected to exhibit swift expansion in the ensuing years, reaching a valuation of $5.84 billion by 2029 with an impressive compound annual growth rate (CAGR) of 10.7%. The anticipated augmentation during this period can be accredited to a rise in cancer survival rates, escalated investments in the support care sector of oncology, the evolution of personalized medicine, an emphasis on multimodal therapies, and an expanding healthcare infrastructure. In the same period, developments in palliative care, the emergence of targeted therapies, technological improvements in drug delivery systems, application of artificial intelligence in drug development, and patient-specific medication are expected to dominate trends.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp
What are the Fundamental Drivers and Innovations Shaping the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The increasing incidence of cancer is anticipated to stimulate the expansion of the cancer anorexia-cachexia syndrome market. Cancer encompasses a vast array of illnesses defined by unregulated cell proliferation and distribution throughout the body. Global cancer incidence is on the rise due to factors such as an aging demographic, lifestyle modifications, environmental exposure, refined detection procedures, elevated awareness, in addition to genetic susceptibility and infections associated with specific cancers. Cancer Anorexia-Cachexia Syndrome (CACS) responds to this growing cancer incidence by focusing on addressing the extreme weight loss and malnutrition commonly observed in cancer sufferers, thereby enhancing their overall life standard and treatment results. For instance, a report published by Macmillan Cancer Support, a UK-based charity, stated in August 2024 that over 3 million people in the UK are living with cancer, a figure expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the escalating rate of cancer is fueling the growth of the cancer anorexia-cachexia syndrome industry. The Effect Of Rising Health Expenditure On The Market
How Is the Cancer Anorexia-Cachexia Syndrome (CACS) Market Segmented?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp
Which Regions Are Driving the Next Phase of the Cancer Anorexia-Cachexia Syndrome (CACS) Market Growth?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Key players in the cancer anorexia-cachexia syndrome market are concentrating on the creation of innovative treatments, such as monoclonal antibody therapies, to improve treatment effectiveness, patient outcomes, and address unknown clinical needs. These therapies utilize antibodies created in a lab to specifically target antigens on cancer cells, which makes the immune system better equipped to identify and combat them. For instance, American pharmaceutical and biotechnology firm, Pfizer Inc., reported promising results from a Stage II clinical trial of ponsegromab, a monoclonal antibody that targets the Growth/Differentiation Factor 15 (GDF-15) in September 2024. This encouraging data provides potential for a fresh therapeutic pathway for patients enduring this devastating illness, as there are presently very few efficient treatments available. The Phase 2 trial data indicates significant advancement in tackling the inflammation processes that lead to muscle wastage and weight loss in cancer patients. This methodology is geared towards not only improving physical capabilities, but also escalating the overall living standards for cancer patients, signifying a crucial advancement in cancer treatment.
View the full report here:
How Is the Cancer Anorexia-Cachexia Syndrome (CACS) Market Defined and What Are Its Core Parameters?
Cancer anorexia-cachexia syndrome (CACS) is a multifactorial condition commonly seen in cancer patients, marked by severe metabolic disturbances. It involves a combination of inflammatory responses, hormonal changes, and altered nutrient utilization, often leading to poor prognosis and treatment resistance.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
